TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT00273013

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GW274150
Description: GW274150 will be available as 30 mg white oval tablets.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GW274150
Description: GW274150 will be available as 30 mg white oval tablets.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Singulair
Description: Singulair will be available as over encapsulated 10 mg orange tablets.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Singulair
Description: Singulair will be available as over encapsulated 10 mg orange tablets.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Singulair
Description: Singulair will be available as over encapsulated 10 mg orange tablets.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Singulair
Description: Singulair will be available as over encapsulated 10 mg orange tablets.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Singulair
Description: Singulair will be available as over encapsulated 10 mg orange tablets.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Singulair
Description: Singulair will be available as over encapsulated 10 mg orange tablets.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Matching placebo for Singulair and GW274150 will be available.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Matching placebo for Singulair and GW274150 will be available.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Matching placebo for Singulair and GW274150 will be available.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Matching placebo for Singulair and GW274150 will be available.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Matching placebo for Singulair and GW274150 will be available.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Matching placebo for Singulair and GW274150 will be available.
Study: NCT03400774

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Stair-climbing
Description: Short bouts of moderate intensity stair-climbing

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Stair-climbing
Description: Short bouts of moderate intensity stair-climbing

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Stair-climbing
Description: Short bouts of moderate intensity stair-climbing

Intervention type: OTHER
Group type: OTHER
Intervention: Stair-climbing
Description: Short bouts of moderate intensity stair-climbing
Study: NCT03818971

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: electroretinogram (flash, pattern and multifocal)
Description: we measured the waves a, b, oscillatory potentials, back ground noise and i for the flash ERG, the waves P50 and N95 for the pattern ERG and the P1, N1 and N2 for the multifocal ERG

Intervention type: OTHER
Group type: OTHER
Intervention: electroretinogram (flash, pattern and multifocal)
Description: we measured the waves a, b, oscillatory potentials, back ground noise and i for the flash ERG, the waves P50 and N95 for the pattern ERG and the P1, N1 and N2 for the multifocal ERG

Intervention type: OTHER
Group type: OTHER
Intervention: electroretinogram (flash, pattern and multifocal)
Description: we measured the waves a, b, oscillatory potentials, back ground noise and i for the flash ERG, the waves P50 and N95 for the pattern ERG and the P1, N1 and N2 for the multifocal ERG
Study: NCT01788774

Intervention type: DRUG
Group type: OTHER
Intervention: Risperidone ISM 50 mg

Intervention type: DRUG
Group type: OTHER
Intervention: Risperidone ISM 75 mg
Study: NCT00073333

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Exposure Treatment
Description: Exposure once per week

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study: NCT04005339

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nanoliposomal Irinotecan
Description: Nanoliposomal irinotecan 70 mg/ IV over 90 minutes, every 14 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Leucovorin
Description: Leucovorin 400 mg/ IV over 30 minutes, every 14 days.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fluorouracil
Description: Fluorouracil 2,400 mg/m IV over 46 hours.
Study: NCT01788774

Intervention type: DRUG
Group type: OTHER
Intervention: Risperidone ISM 100 mg
Study: NCT06745141

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Periodontal surgery
Description: In the intervention group, patients underwent a comprehensive periodontal evaluation conducted by periodontists at a dental clinic. All permanent teeth, except for third molars, were assessed using dental mirrors and periodontal probes. Each tooth was examined at four sites (vestibular, distal, lingual, and mesial) to evaluate visible plaque, probing depth, probing bleeding, and attachment loss.~During the first treatment session, patients were provided with information about periodontal disease, emphasizing the importance of controlling supragingival bacterial biofilms for successful treatment. Plaque-retentive factors (calculus) were removed. Temporary materials were used to restore carious lesions, root remnants were extracted, and maladaptive restorations were adjusted. Supragingival calculus was removed using periodontal scalers, followed by cleaning with a rubber cup, prophylaxis paste, dental floss, and/or interdental brushes. No prophylactic antibiotics were used prior to the
Study: NCT03737890

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Inspiratory Muscle Training
Description: Participants in the experimental group were given Inspiratory Muscle Training by using an IMT device. For this training, the inspiratory load for each participant was set at 30 cmH2O.~In control group, the participants received 3 sets of passive hold- relax pectoral stretch for each session. Each stretch was maintained for 10 seconds with a rest period of 30 seconds given between the sets.~Each participant was supposed to complete a total of 12 sessions of exercises, 3 sessions per week for 4 weeks.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Hold Relax Pectoral Stretch
Description: In control group, the participants received 3 sets of passive hold- relax pectoral stretch for each session. Each stretch was maintained for 10 seconds with a rest period of 30 seconds given between the sets.~Each participant was supposed to complete a total of 12 sessions of exercises, 3 sessions per week for 4 weeks.
Study: NCT06745739

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Life Skills Training Workplace Prevention Program
Description: A workplace health promotion intervention for youth age 16-24, adapted from the school-based Life Skills Training program. The program teaches participants the skills necessary to be productive in work and personal settings while also promoting healthy behaviors and preventing or reducing health risk behaviors. Program content focuses on goal-setting and problem-solving skills, stress and anger management skills, effective communication and conflict management skills, time and financial management, substance use risk reduction, and how to contribute to a healthy, safe, and drug-free workplace.
Study: NCT03465800

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: self-monitoring
Description: self-monitoring of physical activity
Study: NCT02733133

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Testagen® TDS Testosterone 5% HypoSpray®
Description: Topically applied Testosterone Hormone Replacement Lotion
Study: NCT01525680

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Hydrocortisone augmented Prolonged Exposure Therapy
Description: 11 sessions of PE. 20 minutes prior to final eight sessions, 30 mg hydrocortisone is administered.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Prolonged exposure therapy with placebo administration
Description: 11 sessions of PE. 20 minutes prior to final eight sessions, placebo is administered.
Study: NCT00377156

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: radiation therapy
Description: Patients undergo radiation therapy 5 days a week for 2.5 weeks

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: stereotactic radiosurgery

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: stereotactic radiosurgery
Study: NCT00452543

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: acamprosate
Description: Acamprosate 333mg, 2 capsules by mouth (i.e., PO), three times per day (i.e., TID), for 12 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: escitalopram
Description: Escitalopram is given for 12 weeks. Dosing is flexible, starting at 10mg PO once per day (i.e., QD) with the possibility of increasing to 30mg PO QD.
Study: NCT02653092

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Insulin

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Insulin
Study: NCT00452543

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: escitalopram
Description: Escitalopram is given for 12 weeks. Dosing is flexible, starting at 10mg PO once per day (i.e., QD) with the possibility of increasing to 30mg PO QD.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Medical management
Description: Based on the COMBINE study. 1 hour of medical management / behavioral intervention at every study visit (7 times over 12 weeks).

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Medical management
Description: Based on the COMBINE study. 1 hour of medical management / behavioral intervention at every study visit (7 times over 12 weeks).

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo, 2 capsules PO TID, for 12 weeks
Study: NCT00686062

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Control - computerized age-appropriate prenatal testing educational brochure
Description: Computerized version of the age-appropriate prenatal testing educational brochure distributed by the State of California.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: PT Tool - interactive, computerized, prenatal testing decision tool
Description: An interactive, computerized prenatal testing decision-assisting tool (PT Tool).
Study: NCT01584882

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: CATI Tool
Description: Using Screening for drug use, Brief Intervention, Referral to Treatment (SBIRT) as a model, a CATI tool was designed for the Electronic Dental Record which required assessment of 4 variables for patients reporting cigarettes use: 1) number of cigarettes daily, 2) how soon upon waking the first cigarette was smoked, 3) interest in quitting, and 4) previous quit attempts. Level of dependency was calculated and displayed in the health history using the Heavy Smoking Index. Pop-up provider scripts were generated using rule-based algorithms. Links to printable patient education materials on the quit line and on medications to help quit smoking were embedded in the scripts window. The tool automatically recorded tobacco-cessation details.
Study: NCT02664350

Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: CYP2D6
Description: Gentic testing for CYP2D6 metabolic pathway will be performed at baseline.

Intervention type: GENETIC
Group type: ACTIVE_COMPARATOR
Intervention: CYP2D6
Description: Gentic testing for CYP2D6 metabolic pathway will be performed at baseline.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Brief Pain Inventory-Short Form (BPI-SF)
Description: This questionnaire will be completed at baseline and weeks 2, 4, 6 and 8.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Brief Pain Inventory-Short Form (BPI-SF)
Description: This questionnaire will be completed at baseline and weeks 2, 4, 6 and 8.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: M.D. Anderson Symptom Inventory (MDASI)
Description: This questionnaire will be completed at baseline and weeks 2, 4, 6 and 8.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: M.D. Anderson Symptom Inventory (MDASI)
Description: This questionnaire will be completed at baseline and weeks 2, 4, 6 and 8.

Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: OPRM1
Description: Genetic testing of the OPRM1 will be performed after week 8.

Intervention type: GENETIC
Group type: ACTIVE_COMPARATOR
Intervention: OPRM1
Description: Genetic testing of the OPRM1 will be performed after week 8.
Study: NCT01392066

Intervention type: BEHAVIORAL
Intervention: questionnaire
Description: Both the patient and the partner/spouse fill out a questionnaire that assesses their psychosocial adjustment. Time for completion is ca. 30 minutes.~The questionnaire is administered at baseline and 5- and 12-months follow up.
Study: NCT02653092

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Intralipid

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dextrose
Study: NCT01754740

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Uréia
Description: The subjects were randomly divided into two groups:~1. Study Group: 19 patients received topical medication of urea 10% to be applied at the oral cavity 3-4 times per day, during three months.
Study: NCT02653092

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dextrose
Study: NCT01754740

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Control Group: 19 patients received placebo (5% sodium carboxymethylcellulose, 0.15% methyl paraben and 10% glycerol in distilled water qsp 100g) to be applied at the oral cavity 3-4 times per day, during three months.
Study: NCT04674319

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: external cues and cogntive movement strategies
Description: external cueing are sensory stimuli such as auditory (e.g. rhythmic metronome beats) or or visual (e.g. spaced lines on the floor). Cognitive movement strategies refer to focusing attention on a specific parameter of gait (e.g. step length, arm swing).~In the study participants walk under four walking conditions:1)usuall (baseline) walking 2)walking while attending to external cues wich will be applied via metronome beats. The number of beats per minute is adjusted to each participant's steps number per minute. 3)walking with movement cognitive strategy: participants are requested to focus on their step length- and focus on increasing their step length while walking 4) Dual tasking-walking while performing a cognitive task.~During the four walking conditions Brain engegament will be measured, using the single-channel EEG system (Brain-MARC LTD) described in the follwing outcomes measures section.
Study: NCT04100603

Intervention type: OTHER
Intervention: No Intervention
Description: There is no intervention for this study
Study: NCT02653092

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Heparin
Study: NCT05143515

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: PACE label
Description: There were 34 food and drinks choices available for consumption in the pop up café. The labels were displayed next to the food/drink item in the pop up café. The food items were kept in the same position for each participant kitchen to simulate the café environment. Then researchers changed the labels on the display according to the randomisation allocation of each participant. After randomsation participants were informed that they have £10 to spend in the pop-up café and that they could eat the food they selected in a private social eating room.
Study: NCT02653092

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Heparin

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: GnRH

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GnRH

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Hyperinsulinemic Euglycemic Clamp
Study: NCT03465800

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: self-monitoring
Description: self-monitoring of physical activity

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: self-monitoring
Description: self-monitoring of physical activity

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: daily incentives
Description: daily incentive payments for physical activity
Study: NCT02071147

Intervention type: OTHER
Group type: OTHER
Intervention: No Clinical Follow up

Intervention type: OTHER
Group type: OTHER
Intervention: Quality of Life questionnaire

Intervention type: OTHER
Group type: OTHER
Intervention: Quality of Life questionnaire

Intervention type: OTHER
Group type: OTHER
Intervention: Patient satisfaction Questionnaire
Description: Conducted at Research clinic.

Intervention type: OTHER
Group type: OTHER
Intervention: Patient satisfaction Questionnaire
Description: Conducted at Research clinic.
Study: NCT04376177

Intervention type: DIAGNOSTIC_TEST
Intervention: Ultrasound
Description: Echodoppler imaging of upper limbs performed by trained operators at rest and during provocative maneuvers for TOS diagnosis.

Intervention type: DIAGNOSTIC_TEST
Intervention: angiography
Description: Angiography (arterial and/or venous) of upper limbs performed by trained operators at rest and during provocative maneuvers such for TOS diagnosis.

Intervention type: DIAGNOSTIC_TEST
Intervention: questionnaires
Description: Use of standard questionnaires (MASC, DASH, SF36) for the evaluation of upper limb symptoms self-completed by the patients at admission.

Intervention type: DIAGNOSTIC_TEST
Intervention: Transcutaneous oximetry
Description: Mesurement of transcutaneuos oxygen pressure on both forearms performed at rest and during provocative maneuversfor TOS diagnosis.

Intervention type: DIAGNOSTIC_TEST
Intervention: plethysmography
Description: Photoplethysmography of the forearms or fingers performed at rest and during provocative maneuvers for TOS diagnosis

Intervention type: DIAGNOSTIC_TEST
Intervention: Electromyogram
Description: Electromyography of the upper limbs with encoding of the physician for the presence or abnsence of signs of plexis compression (impairment of the response on C8 T1 erea

Intervention type: DIAGNOSTIC_TEST
Intervention: Standard X-Ray
Description: Standard X-Ray performed for the research of apophysomegaly or additionnal cervical rib.
Study: NCT02746367

Intervention type: OTHER
Intervention: Diagnostic test (LDT)
Description: Proteomic assay

Intervention type: OTHER
Intervention: Diagnostic test (LDT)
Description: Proteomic assay

Intervention type: OTHER
Intervention: Diagnostic test (LDT)
Description: Proteomic assay
Study: NCT02092272

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: instructional exercise video source
Description: instructional exercise video source
Study: NCT00188331

Intervention type: BEHAVIORAL
Intervention: Neuropsychological Testing
Description: neuropsychological testing with traditional tests, CANTAB and six elements test as well as questionnaires

Intervention type: BEHAVIORAL
Intervention: Neuropsychological Testing
Description: neuropsychological testing with traditional tests, CANTAB and six elements test as well as questionnaires

Intervention type: BEHAVIORAL
Intervention: Neuropsychological Testing
Description: neuropsychological testing with traditional tests, CANTAB and six elements test as well as questionnaires
Study: NCT03694730

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Exercise Treatment
Description: Exercise treatment will consist of squatting and knee extension exercises, designed to progressively load the patellar tendon (Heavy-Slow Resistance protocol). A pain-monitoring model is used to guide exercise loads. As the protocol progresses, exercise load is increased while repetitions are decreased.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exercise Treatment
Description: Exercise treatment will consist of squatting and knee extension exercises, designed to progressively load the patellar tendon (Heavy-Slow Resistance protocol). A pain-monitoring model is used to guide exercise loads. As the protocol progresses, exercise load is increased while repetitions are decreased.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pain- Guided Activity Modification
Description: Participants sports participation and physical activity will be guided by the Pain-Monitoring Model. Using the Pain-Monitoring Model, patients may participate in activities that cause patellar tendon pain, as long as pain does not exceed 5/10 on the numeric pain rating scale (NPRS) (0 = No pain, 10 = Worst pain imaginable) during or immediately after activity. Additionally, pain should return to pre-activity levels by the following morning and pain should not increase from week-to-week.
Study: NCT04527744

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: the injection of onabotulinumtoxinA at different point
Description: For experimental group, Three units of onabotulinumtoxinA (BTX-A) per site (90 hemifaces) will be initially injected at the Yonsei point. For control group，the same dose of BTX will be injected into the levator labii superioris alaeque nasi muscle, and the injection point is located 3 to 5 mm lateral to each nostril, which was a classical injection point of this treatment.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: the injection of onabotulinumtoxinA at different point
Description: For experimental group, Three units of onabotulinumtoxinA (BTX-A) per site (90 hemifaces) will be initially injected at the Yonsei point. For control group，the same dose of BTX will be injected into the levator labii superioris alaeque nasi muscle, and the injection point is located 3 to 5 mm lateral to each nostril, which was a classical injection point of this treatment.
Study: NCT04083079

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PEG-rhG-CSF
Description: Patients will be given PEG-rhG-CSF for primary/secondary prevention each cycle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: rhG-CSF
Description: Patients will be given rhG-CSF for either primary/secondary prevention or treatment once any neutropenia each cycle.
Study: NCT02810743

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ddAC-CP-Olaparib
Description: ddAC-CP-Olaparib

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ddAC-mini CTC
Description: ddAC - mini CTC
Study: NCT02233946

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: computer-facilitated brief intervention
Description: Immediate feedback to patient of screening results and risk for substance use problem, followed by 11 pages of science and true-life stories about health risks of adolescent substance use. Screening results then go to provider who reviews them with patient and gives brief counseling, and refers to an online motivational enhancement therapy intervention for patients at moderate/high risk for substance use problems.
Study: NCT01918722

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ICH-1(herbal medicine with Hirudo, Tabanus)
Description: 8herbals (with 2 herbals of Activating blood stagnation and expelling blood stasis herbs) one dose, bid, for 10 days

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: placebo herbal medicine, one dose,bid, for 10 days

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ICH-2(herbal medicine without Hirudo, Tabanus)
Description: (6herbals, without 2 herbals of promoting blood stasis) one dose, bid, for 10 days